Format

Send to

Choose Destination
Oncotarget. 2016 Mar 15;7(11):12289-304. doi: 10.18632/oncotarget.6935.

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

Author information

1
Department of Pulmonary Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
2
Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.

Abstract

During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been reported to be highly effective and well tolerated in these patients. However, resistance to crizotinib emerges years after treatment, and increasing efforts have been made to overcome this issue. Here, we review the biology of ALK and ROS1 and their roles in cancer progression. We also summarize the ongoing and completed clinical trials validating ALK and ROS1 as targets for cancer treatment. In the last section of the review, we will discuss the molecular mechanisms of crizotinib resistance and focus approaches to overcome it. This review describes an exciting new area of research and may provide new insights for targeted cancer therapies.

KEYWORDS:

ROS1 kinase; anaplastic lymphoma kinase; crizotinib; drug resistance; non-small cell lung cancer

PMID:
26802023
PMCID:
PMC4914285
DOI:
10.18632/oncotarget.6935
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center